NCI-H1944 Cell Line

Brief Introduction
Product List

General Information
Organism	Homo sapiens, human
Cell Line Description	NCI-H1944 is a human non-small cell lung cancer (adenocarcinoma subtype) cell line, established in June 1988 at the NCI–Navy Medical Oncology Branch—a joint venture between the National Cancer Institute (NCI) and the U.S. Navy. The cell line was derived from a soft-tissue metastasis in a 62-year-old Caucasian female patient who had stage 3B disease and a prior history of radiation therapy. These cells grow as an adherent monolayer and exhibit epithelial-like characteristics. Their genomic profile includes a heterozygous KRAS p.Gly13Asp activating mutation, a truncating ATR variant, and additional alterations in the STK11, KEAP1, CDKN2A, and RBM10 genes. The cell line is microsatellite-stable (MSS), near-diploid, and capable of forming subcutaneous tumors in athymic nude mice. NCI-H1944 is widely used in research areas such as signaling pathways in KRAS-mutant lung cancer, KRAS-targeted therapeutic strategies, receptor tyrosine kinase (RTK) profiling, three-dimensional (3D) spheroid culture, and high-throughput pharmacogenomic screening. Furthermore, it is utilized in studies involving the co-targeting of MYC and HIF-1α, as well as in the preclinical in vivo evaluation of candidate therapeutic agents for KRAS-mutant lung cancer, frequently serving as a reference model within research panels for this cancer type.
Tissue	Lung; derived from a soft tissue metastasis
Disease	Lung Adenocarcinoma (Non-Small Cell Lung Carcinoma); stage 3B
Morphology	Epithelial-like
Gender	Female
Age	62 years
Ethnicity	Caucasian
Product Format	Frozen
Growth Mode	Adherent
Biosafety Level	1 (Biosafety classification is based on U.S. Public Health Service Guidelines)
Applications	1. Mutant-KRAS non-small cell lung cancer signaling and synthetic-lethal studies 2. Preclinical evaluation of KRAS-targeted agents in subcutaneous xenograft models 3. MYC and HIF-1α co-targeting and antitumor efficacy studies 4. Receptor tyrosine kinase and phosphotyrosine signaling profiling in lung cancer 5. High-throughput drug sensitivity and pharmacogenomic screening 6. Three-dimensional spheroid and spheroid-based drug response culture
Shipped In	Dry ice
Storage Temperature	−196°C
Characteristics
Tumorigenic	Yes, forms subcutaneous tumors in athymic nude mice
Karyotype	Near-diploid (ploidy approximately 2.1 by SNP6 and whole-exome analysis); modal chromosome number not reported. Deep deletions of SMARCA4 (19p13.2) and CDKN2A/CDKN2B (9p21.3)
Expression Markers	Cytokeratin positive; expresses mutant KRAS G13D protein
Mycoplasma Test	Negative
Culture Conditions and Handling
Subculturing	1. Remove and discard the culture medium. 2. Briefly rinse the cell monolayer with PBS (Ca²⁺/Mg²⁺-free) to thoroughly remove residual serum. 3. Add 2.0 to 3.0 mL of 0.25% Trypsin–0.53 mM EDTA solution, and observe under an inverted microscope until the cell monolayer has dispersed (typically takes 2 to 5 minutes). 4. Add 6.0 to 8.0 mL of complete growth medium, and gently pipette to prepare a single-cell suspension. 5. Aliquot the cell suspension into new culture vessels.
Medium Renewal	Every 2 to 3 days
Subcultivation Ratio	A split ratio of 1:3 to 1:6 is recommended.
Culture Conditions	Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C
Cryopreservation	Complete growth medium supplemented with 5% (v/v) DMSO

Cat.No.	Product Name	Price
CSC-RR01002	GFP/Luc Reporter Cell Line - NCI-H1944	Inquiry

The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.

* For research use only. Not intended for any clinical use.

Quick Inquiry